^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

LY2109761

i
Other names: LY2109761
Company:
Eli Lilly
Drug class:
TGF-β R2 kinase inhibitor, TGF-β RI kinase inhibitor
3d
Combination of polymeric micelle formulation of TGFβ receptor inhibitors and paclitaxel produces consistent response across different mouse models of Triple-negative breast cancer. (PubMed, Bioeng Transl Med)
Here, we evaluated combination treatments using experimental TGFR inhibitors (TGFβi), SB525334 (SB), and LY2109761 (LY) with paclitaxel (PTX) chemotherapy. Genetic profiling of the tumors revealed differences in the expression levels of genes associated with TGFβ, epithelial to mesenchymal transition (EMT), TLR-4, and Bcl2 signaling, alluding to the susceptibility to specific gene signatures to the treatment. Taken together, our study suggests that TGFβi and PTX combination therapy using high-capacity POx micelle delivery provides a robust antitumor response in multiple TNBC subtype mouse models.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TGFB1 (Transforming Growth Factor Beta 1) • TLR4 (Toll Like Receptor 4) • TGFBI (Transforming Growth Factor Beta Induced)
|
paclitaxel • LY2109761
1m
AMIGO2 enhances the invasive potential of colorectal cancer by inducing EMT. (PubMed, Cancer Gene Ther)
Activation of the TGFβ/Smad signaling pathway was found involved in AMIGO2-induced EMT, and treatment with the TGFβ receptor inhibitor LY2109761 suppressed AMIGO2-induced EMT...These results suggest that the nuclear translocation of AMIGO2 induces EMT to promote CRC invasion by activating the TGFβ/Smad signaling pathway. Thus, AMIGO2 is an attractive therapeutic target for inhibiting EMT and metastatic CRC progression.
Journal
|
HMGB1 (High Mobility Group Box 1) • AMIGO2 (Adhesion Molecule With Ig Like Domain 2)
|
LY2109761
11ms
Pirfenidone inhibits TGF-β1-induced metabolic reprogramming during epithelial-mesenchymal transition in non-small cell lung cancer. (PubMed, J Cell Mol Med)
To elucidate the underlying mechanism, we compared the efficacy of PFD after pretreatment with either TGF-β1 or a TGF-β receptor inhibitor (LY2109761). Additionally, PFD combined with cisplatin targeted TGF-β1 to inhibit glycolysis during EMT and enhanced the chemosensitization of A549 and H1299 cells. The magnitude of the anticancer effect exhibited by PFD was intricately linked to its metabolic properties.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
|
cisplatin • LY2109761
12ms
Primary cilium participates in radiation-induced bystander effects through TGF-β1 signaling. (PubMed, J Cell Physiol)
The TGF-β1 signaling was interfered by LY2109761, a TGF-β receptor 1 (TβR1) inhibitor, or TGF-β1 neutral antibody...IFT88 siRNA or KIF3a siRNA impaired PC formation resulted in an aggravated DNA damage in bystander cells, while elevated PC formation by CytoD or STIL siRNA resulted in a decrease of DNA damage. Furthermore, TGF-β1 induced more DNA damages in S phases cells which showed lower PC formation rate and less DNA damages in G /G phase cells which showed higher PC formation rate. This study demonstrates the particular role of primary cilia during RCM induced DNA damages through TGF-β1 signaling restriction and thereby provides a functional link between primary cilia and RIBEs.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
|
LY2109761
1year
Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling. (PubMed, Front Med)
Collectively, although TEXs lead to the initial activation of CAR T-cells, the effect of TEXs suppressed CAR T-cells, which can be rescued by LY2109761. A treatment regimen combining CAR T-cell therapy and TGF-β inhibitors might be a novel therapeutic strategy for refractory and relapsed B-cell lymphoma.
Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TGFB1 (Transforming Growth Factor Beta 1) • SMAD3 (SMAD Family Member 3)
|
LAG3 expression • HAVCR2 expression
|
LY2109761
over1year
Smoking-related epigenetic modifications are associated with the prognosis and chemotherapeutics of patients with bladder cancer. (PubMed, Int J Immunopathol Pharmacol)
Totally, we initially identified the smoking-related epigenetic modifications in bladder cancer and constructed a corresponding prognostic model, which was also linked to disparate sensitivities to chemotherapeutics. Our findings would provide novel insights into the carcinogenesis, prognosis, and therapies in bladder cancer.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12
|
cisplatin • gemcitabine • buparlisib (AN2025) • LY2109761
2years
Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop. (PubMed, J Exp Clin Cancer Res)
Irradiation can induce ESCC cells secreting DJ-1. Secreted DJ-1 enters bystander cells to initiate activation of the TGF-β1 pathway via the DJ-1/HSC70/Smad3 signaling axis. The TSP1/TGF-β1/Smad3 positive feedback pathway constitutes the core pathway that promotes ESCC metastasis. DJ-1 is a useful biomarker for predicting the efficacy of radiotherapy and a potential therapeutic target for reversing RIBE in ESCC. Schematic diagram showing the underlying mechanism that irradiation-induced secretion of DJ-1 accelerates the metastasis of bystander ESCC cells.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • SMAD3 (SMAD Family Member 3)
|
LY2109761
over2years
TGF-β-induced FLRT3 attenuation is essential for cancer-associated fibroblast-mediated epithelial-mesenchymal transition in colorectal cancer. (PubMed, Mol Cancer Res)
Implications: CAFs enhance CRC aggressiveness by reducing FLRT3 expression through activating TGF-β/SMAD4 signaling pathway. CAFs-targeted therapy and/or LY2109761 were promising treatments for CRC.
Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • SMAD4 (SMAD family member 4) • CDH1 (Cadherin 1) • FN1 (Fibronectin 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
CD8 expression • IFNG expression
|
LY2109761
over2years
Effect of ALA-PDT on inhibition of oral precancerous cell growth and its related mechanisms. (PubMed, Lasers Med Sci)
ALA-PDT suppresses the growth of oral precancerous cells by regulating the TGF-β signaling pathway, and its suppressive effect was enhanced using LY2109761. These results indicate that it could be a promising alternative treatment against oral precancerous lesions.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
|
LY2109761
over2years
Heat stress and hypoxia inhibit the secretion of androgens and induce epithelial-to-mesenchymal transition associated with activated TGF-β/Smad signaling in canine cryptorchidism. (PubMed, Reprod Domest Anim)
Use of LY2109761, a receptor inhibitor of TGF-βs/Smad signaling pathway, was associated with heat stress and COCl suppression of androgens' secretion and stimulated EMT in Leydig cells. These findings characterized a novel pathogenesis of cryptorchidism and provided a new idea for therapeutics.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • VIM (Vimentin) • TGFB1 (Transforming Growth Factor Beta 1) • HSPA4 (Heat Shock Protein Family A (Hsp70) Member 4) • SMAD3 (SMAD Family Member 3)
|
VIM expression
|
LY2109761
over2years
PROGNOSTIC RELEVANCE AND ANTITUMOR OR IMMUNITY OF NSD3 OVEREXPRESSION IN THE BREAST CANCER (GBCC 2022)
WHSC1L1 overexpression could play potential roles in the progression of breast cancer, and targeting WHSC1L1 could be a potential strategy for the treatment of breast cancer.
PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • NSD3 (Nuclear Receptor Binding SET Domain Protein 3)
|
PD-L1 expression • NSD3 overexpression
|
erlotinib • VTX-11e • LY2109761 • CZC24832
over3years
Bone marrow mesenchymal stem cells in microenvironment transform into cancer-associated fibroblasts to promote the progression of B-cell acute lymphoblastic leukemia. (PubMed, Biomed Pharmacother)
In vitro experiments, bone marrow mesenchymal stem cells (BM-MSCs) acquired a CAFs phenotype after co-culture with leukemia cells, which produced high level of tumor-promoting growth factors and reduced the daunorubicin (DNR)-induced damage to B-ALL cells...Further LY2109761 and AMD3100 effectively decreased the activation of CAFs through inhibiting TGF-β receptor and CXCR4. Comparative experiments with MSCs and transformed CAFs prompted that CAFs had more obvious effect than MSCs on stimulating leukemia progression through accelerating leukemia cell migration and invasion. These results clarified the important role of CAFs in B-ALL progression and the possible mechanisms of CAFs activation in leukemia microenvironment, which might provide a theoretical basis for B-ALL patients to find more effective targeted therapies targeting the bone marrow microenvironment.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • TGFB1 (Transforming Growth Factor Beta 1)
|
daunorubicin • LY2109761 • plerixafor